达卡巴嗪-话题@MedSci

#达卡巴嗪#

7篇内容 | 1362人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2256466, encodeId=f2a122564663a, content=<a href='/topic/show?id=bf079890912' target=_blank style='color:#2F92EE;'>#霍奇金淋巴瘤#</a> <a href='/topic/show?id=11ee432923f' target=_blank style='color:#2F92EE;'>#多柔比星#</a> <a href='/topic/show?id=43e293919b1' target=_blank style='color:#2F92EE;'>#达卡巴嗪#</a> <a href='/topic/show?id=fc2be734870' target=_blank style='color:#2F92EE;'>#纳武利尤单抗#</a> <a href='/topic/show?id=f9d39696957' target=_blank style='color:#2F92EE;'>#长春碱#</a>, objectTitle=JCO：纳武利尤单抗联合多柔比星、长春碱、达卡巴嗪作为老年霍奇金淋巴瘤患者一线治疗的II期试验, objectType=article, longId=867612, objectId=deca86e612e9, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20250227/e71e95eb42aa4f57b5850381081970d5-blDysZFKkGsr.jpg, objectUrl=/article/show_article.do?id=deca86e612e9, replyNumber=0, likeNumber=22, createdTime=2025-03-17, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=deca86e612e9, moduleTitle=JCO：纳武利尤单抗联合多柔比星、长春碱、达卡巴嗪作为老年霍奇金淋巴瘤患者一线治疗的II期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=deca86e612e9)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2197151, encodeId=b639219e15194, content=<a href='/topic/show?id=43e293919b1' target=_blank style='color:#2F92EE;'>#达卡巴嗪#</a> <a href='/topic/show?id=a865e823050' target=_blank style='color:#2F92EE;'>#经典霍奇金淋巴瘤#</a> <a href='/topic/show?id=807311311593' target=_blank style='color:#2F92EE;'>#BV#</a>, objectTitle=【Blood】BV联合达卡巴嗪或O药一线治疗不适合化疗的老年cHL效果良好, objectType=article, longId=820367, objectId=b90882036e8f, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221109/1668016299208_4754896.png, objectUrl=/article/show_article.do?id=b90882036e8f, replyNumber=0, likeNumber=63, createdTime=2024-04-06, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=b90882036e8f, moduleTitle=【Blood】BV联合达卡巴嗪或O药一线治疗不适合化疗的老年cHL效果良好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b90882036e8f)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2172352, encodeId=17bd21e235220, content=<a href='/topic/show?id=43e293919b1' target=_blank style='color:#2F92EE;'>#达卡巴嗪#</a> <a href='/topic/show?id=a865e823050' target=_blank style='color:#2F92EE;'>#经典霍奇金淋巴瘤#</a> <a href='/topic/show?id=47ce108123f5' target=_blank style='color:#2F92EE;'>#维布妥昔单抗#</a>, objectTitle=Blood：维布妥昔单抗联合达卡巴嗪或O药一线治疗≥60岁不适合化疗cHL的2期研究, objectType=article, longId=802329, objectId=9a9a8023295b, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/patient-meeting-a-doctor-PAYSRMZ.jpg, objectUrl=/article/show_article.do?id=9a9a8023295b, replyNumber=0, likeNumber=121, createdTime=2023-12-01, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=9a9a8023295b, moduleTitle=Blood：维布妥昔单抗联合达卡巴嗪或O药一线治疗≥60岁不适合化疗cHL的2期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9a9a8023295b)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1967136, encodeId=b896196e136e3, content=<a href='/topic/show?id=43e293919b1' target=_blank style='color:#2F92EE;'>#达卡巴嗪#</a>, objectTitle=Br J Cancer：免疫检查点抑制剂ICI预治疗提高达卡巴嗪治疗转移性黑色素瘤的疗效, objectType=article, longId=214405, objectId=fc05214405fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc05214405fd, replyNumber=0, likeNumber=99, createdTime=2022-03-19, rootId=0, userName=huanbaofeng, userId=e729101, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc05214405fd, moduleTitle=Br J Cancer：免疫检查点抑制剂ICI预治疗提高达卡巴嗪治疗转移性黑色素瘤的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fc05214405fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1967134, encodeId=4829196e13440, content=<a href='/topic/show?id=43e293919b1' target=_blank style='color:#2F92EE;'>#达卡巴嗪#</a>, objectTitle=Brit J Cancer：平滑肌肉瘤患者艾日布林与达卡巴嗪的疗效比较, objectType=article, longId=166026, objectId=12ce166026c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=12ce166026c3, replyNumber=0, likeNumber=81, createdTime=2019-09-14, rootId=0, userName=huanbaofeng, userId=e729101, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=12ce166026c3, moduleTitle=Brit J Cancer：平滑肌肉瘤患者艾日布林与达卡巴嗪的疗效比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=12ce166026c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1967135, encodeId=a089196e135a8, content=<a href='/topic/show?id=43e293919b1' target=_blank style='color:#2F92EE;'>#达卡巴嗪#</a>, objectTitle=Blood：本妥昔单抗维多汀、阿霉素、长春碱联合达卡巴嗪治疗非大体积局限性霍奇金淋巴瘤的疗效和安全性, objectType=article, longId=168967, objectId=04af16896e43, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=04af16896e43, replyNumber=0, likeNumber=91, createdTime=2020-01-28, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=04af16896e43, moduleTitle=Blood：本妥昔单抗维多汀、阿霉素、长春碱联合达卡巴嗪治疗非大体积局限性霍奇金淋巴瘤的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=04af16896e43)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1967133, encodeId=ac77196e1331e, content=<a href='/topic/show?id=43e293919b1' target=_blank style='color:#2F92EE;'>#达卡巴嗪#</a>, objectTitle=EUR J Cancer：患者衍生的纤维肿瘤异种移植物预测肿瘤细胞对多柔比星/达卡巴嗪的高度敏感性, objectType=article, longId=125179, objectId=5de61251e930, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5de61251e930, replyNumber=0, likeNumber=84, createdTime=2018-10-03, rootId=0, userName=huanbaofeng, userId=e729101, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5de61251e930, moduleTitle=EUR J Cancer：患者衍生的纤维肿瘤异种移植物预测肿瘤细胞对多柔比星/达卡巴嗪的高度敏感性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5de61251e930)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1967132, encodeId=e976196e132a6, content=<a href='/topic/show?id=43e293919b1' target=_blank style='color:#2F92EE;'>#达卡巴嗪#</a>, objectTitle=Blood：brentuximab vedotin联合达卡巴嗪或苯达莫司汀用于HL老年患者的安全性和治疗效果。, objectType=article, longId=116500, objectId=e5fb11650085, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e5fb11650085, replyNumber=0, likeNumber=87, createdTime=2018-04-14, rootId=0, userName=huanbaofeng, userId=e729101, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e5fb11650085, moduleTitle=Blood：brentuximab vedotin联合达卡巴嗪或苯达莫司汀用于HL老年患者的安全性和治疗效果。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e5fb11650085)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1967131, encodeId=8955196e131ce, content=<a href='/topic/show?id=43e293919b1' target=_blank style='color:#2F92EE;'>#达卡巴嗪#</a>, objectTitle=Lancet：黑色素瘤新药binimetinib与达卡巴嗪临床研究, objectType=article, longId=91539, objectId=570491539a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=570491539a0, replyNumber=0, likeNumber=89, createdTime=2017-08-12, rootId=0, userName=huanbaofeng, userId=e729101, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=570491539a0, moduleTitle=Lancet：黑色素瘤新药binimetinib与达卡巴嗪临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=570491539a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1967130, encodeId=4795196e13005, content=<a href='/topic/show?id=43e293919b1' target=_blank style='color:#2F92EE;'>#达卡巴嗪#</a>, objectTitle=BMC Cancer：司美替尼联合达卡巴嗪用于转移性葡萄膜黑色素瘤的临床研究, objectType=article, longId=52070, objectId=9fac520e0b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9fac520e0b0, replyNumber=0, likeNumber=73, createdTime=2015-10-01, rootId=0, userName=huanbaofeng, userId=e729101, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9fac520e0b0, moduleTitle=BMC Cancer：司美替尼联合达卡巴嗪用于转移性葡萄膜黑色素瘤的临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9fac520e0b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

达卡巴嗪

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#霍奇金淋巴瘤# #多柔比星# #达卡巴嗪# #纳武利尤单抗# #长春碱#

JCO：纳武利尤单抗联合多柔比星、长春碱、达卡巴嗪作为老年霍奇金淋巴瘤患者一线治疗的II期试验

2025-03-17发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#达卡巴嗪# #经典霍奇金淋巴瘤# #BV#

【Blood】BV联合达卡巴嗪或O药一线治疗不适合化疗的老年cHL效果良好

2024-04-06发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#达卡巴嗪# #经典霍奇金淋巴瘤# #维布妥昔单抗#

Blood：维布妥昔单抗联合达卡巴嗪或O药一线治疗≥60岁不适合化疗cHL的2期研究

2023-12-01发表于上海

huanbaofeng (审核中...)

前往app查看评论内容

#达卡巴嗪#

Br J Cancer：免疫检查点抑制剂ICI预治疗提高达卡巴嗪治疗转移性黑色素瘤的疗效

2022-03-19

huanbaofeng (审核中...)

前往app查看评论内容

#达卡巴嗪#

Brit J Cancer：平滑肌肉瘤患者艾日布林与达卡巴嗪的疗效比较

2019-09-14

zhaojie88 (审核中...)

前往app查看评论内容

#达卡巴嗪#

Blood：本妥昔单抗维多汀、阿霉素、长春碱联合达卡巴嗪治疗非大体积局限性霍奇金淋巴瘤的疗效和安全性

2020-01-28

huanbaofeng (审核中...)

前往app查看评论内容

#达卡巴嗪#

EUR J Cancer：患者衍生的纤维肿瘤异种移植物预测肿瘤细胞对多柔比星/达卡巴嗪的高度敏感性

2018-10-03

huanbaofeng (审核中...)

前往app查看评论内容

#达卡巴嗪#

Blood：brentuximab vedotin联合达卡巴嗪或苯达莫司汀用于HL老年患者的安全性和治疗效果。

2018-04-14

huanbaofeng (审核中...)

前往app查看评论内容

#达卡巴嗪#

Lancet：黑色素瘤新药binimetinib与达卡巴嗪临床研究

2017-08-12

huanbaofeng (审核中...)

前往app查看评论内容

#达卡巴嗪#

BMC Cancer：司美替尼联合达卡巴嗪用于转移性葡萄膜黑色素瘤的临床研究

2015-10-01

科室
- - 订阅+
  - 更多科室
工具
服务